Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
follicle stimulating hormone · 1 trial · 1 indication
Whether higher progesterone levels on the day of trigger will lead to rapid rise of progesterone after ovulation induction compared to lower progesterone levels.
| Arm | Type | Description |
|---|---|---|
| Control group | ACTIVE_COMPARATOR | Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (13). The stimulation dosage will remain unchanged until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm). |
| Study group | EXPERIMENTAL | Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (LaMarca et al.). As soon as ≥ 3 follicle of a size of 14mm are seen, the stimulation dosage will be reduced daily by 12.5 IU recFSH until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm). |
| Name | Type | Description |
|---|---|---|
| follicle stimulating hormone | DRUG | Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged |
Inclusion Criteria: * Primary / secondary infertility with the indication for IVF/ICSI * Patients age 18 - 40 years * 60 kg up to and including 90 kg * BMI of 18-32 kg/m2 * Menstrual cycle length of 24-35 days Exclusion Criteria: An individual who meets any of the following criteria will be exclu...
Follicle stimulating hormone is being studied for use in progesterone resistance. It is an investigational small molecule in Phase 1 clinical development, being evaluated in a completed early Phase 1 trial that enrolled 127 participants.
Merck & Company, Inc. (NYSE: MRK) is developing follicle stimulating hormone. The company is conducting clinical research on this investigational small molecule for progesterone resistance.
Follicle stimulating hormone is in Phase 1 clinical development. It is an investigational drug, not yet approved, and has completed an early Phase 1 trial. The study was a randomized, active-controlled trial that enrolled 127 participants.
Follicle stimulating hormone has one completed clinical trial, NCT03356964, titled "Step Down FSH Approach and Late Follicular Phase in Progesterone Level." This early Phase 1 study enrolled 127 female participants in the United Arab Emirates and included healthy volunteers.
Follicle stimulating hormone is commonly abbreviated as FSH. In the clinical trial NCT03356964, the study title refers to the "Step Down FSH Approach," indicating that FSH is the same agent as follicle stimulating hormone.